Cyclodextrin- and calixarene-based polycationic amphiphiles as gene delivery systems: a structure–activity relationship study†

Laura Gallego-Yerga,a Michela Lomazzi,b Valentina Franceschi,c Francesco Sansone,⁎b Carmen Ortiz Mellet,*a Gaetano Donofrio,*c Alessandro Casnati⁠b and José M. García Fernández*<d

Multi-head/multi-tail facial amphiphiles built on cyclodextrin (CD) and calixarene (CA) scaffolds are paradigmatic examples of monodisperse gene delivery systems. The possibility to precisely control the architectural features at the molecular level offers unprecedented opportunities for conducting structure–activity relationship studies. A major requirement for those channels is the design of a sufficiently diverse ensemble of compounds for parallel evaluation of their capabilities to condense DNA into transfection nanoparticles where the gene material is protected from the environment. Here we have undertaken the preparation of an oriented library of β-cyclodextrin (βCD) and calix[4]arene (CA4) vectors with facial amphiphilic character designed to ascertain the effect of the cationic head nature (aminothiourea-, arginine- or guanidine-type groups) and the macrocyclic platform on the abilities to complex plasmid DNA (pDNA) and in the efficiency of the resulting nanocomplexes to transfect cells in vitro. The hydrophobic domain, formed by hexanoyl or hexyl chains, remains constant in each series, matching the overall structure found to be optimal in previous studies. DLS, TEM and AFM data support that all the compounds self-assemble in the presence of pDNA through a process that involves initially electrostatic interactions followed by formation of βCD or CA4 bilayers between the oligonucleotide filaments. Spherical transfective nanoparticles that are monomolecular in DNA are thus obtained. Evaluation in epithelial COS-7 and human rhabdomyosarcoma RD-4 cells evidenced the importance of having primary amino groups in the vector to warrant high levels of transfection, probably because of their buffering capacity. The results indicate that the optimal cationic head depends on the macrocyclic core, aminothiourea groups being preferred in the βCD series and arginine groups in the CA4 series. Whereas the transfection efficiency relationships remain essentially unchanged within each series, irrespective of the cell type, the optimal platform (βCD or CA4) strongly depends on the cell type. The results illustrate the potential of monodisperse vector prototypes and diversity-oriented strategies on identifying the optimal candidates for gene therapy applications.

Introduction

Gene therapy represents a potent tool for the therapeutic treatment of a broad range of genetic and acquired diseases. After some controversial failures, the last few years have witnessed the first really successful applications of this technique, opening the possibility to fight pathologies like severe immunodeficiencies, the Wiskott–Aldrich syndrome, beta-thalassaemia, haemophilia, adenoleukodystrophy and several types of cancer, with an ever increasing number of clinical trials under way. In most cases, the delivery of genetic material aimed at the correction of defects in the patients’ cell genome is performed by using viruses as vectors in the context of an “ex vivo” strategy. Adenoviruses and retroviruses are properly modified to
eliminate their infectiousness and to incorporate the therapeutic sequences. Their efficiency in transfecting cells, due to their own nature, does the rest. Yet, the use of viral vectors is still accompanied by some not negligible risks, such as violent adverse immune responses and genotoxicity,\(^3\) and limits like compound and expensive preparation processes, production in rather scarce quantities, restricted dimensions of the nucleic acid filaments that can be transported or possible compromised bioavailability because of their large molecular size. These not yet resolved problems fuelled the research for alternatives that materialized, in the years, in the development of non-viral gene vectors based initially on cationic lipids and then on cationic polymers, dendrimers and nanoparticles.\(^4\) Among them, some have shown relevant efficiency and relatively low toxicity and are widely used in transfection protocols. Nevertheless, although some outstanding examples are on record,\(^5\) the systems proposed so far cannot really replace viruses. For these reasons, the efforts in the development of new molecules and formulations able to deliver nucleic acids into cells with increasing efficiency and safety as of today are still ongoing.

A main difficulty in non-viral gene carrier optimization strategies is the multicomponent or polydisperse nature and random conformational properties of most of the systems that are currently available, which handicaps establishing reliable relationships between chemical structure and transfection efficiency. The design of monodisperse, molecularly well-defined gene vector prototypes, while more challenging, offers unprecedented opportunities in this respect. In recent years, cyclodextrins (CDs) and calixarenes (CAs) have been proposed as central frameworks allowing the controlled incorporation of nucleic acid complexation elements.\(^6\) While some positive results using polycationic hydrophilic derivatives have been reported,\(^7\) we and others have shown that endowing the vector architecture with facial amphiphilicity,\(^8\) by installing segregated clusters of cationizable and hydrophobic groups at opposite rims in the macrocyclic cores, significantly improves the nucleic acid condensation abilities and the transfection efficiency of the resulting supramolecular nanocomplexes (Fig. 1).\(^9\)–\(^12\)

Structure–activity relationship studies independently conducted in both series of compounds allowed identification of some favourable structural features. Thus, \(\beta\)-cyclodextrin (\(\beta\)CD)-based architectures were generally superior to \(\alpha\)CD or \(\gamma\)CD derivatives\(^13\) and dispositions having the cationic heads at the primary face and the lipophilic tails at the secondary hydroxyls (skirt-type arrangement)\(^14\) performed better than analogues exhibiting the reversal orientation.\(^15\) In the polycationic amphiphilic CA family, the reports point to the supremacy of the calix[4]arene (CA\(_4\)) core in the cone conformation with the protonable groups at the upper rim.\(^16\) The combination of thiourea and amine groups at the cationic domain was found optimal for \(\beta\)CD derivatives,\(^17\) whereas arginine clustering imparted the highest DNA delivery efficiency in the CA\(_4\) series.\(^16\) Copper(I)-catalyzed azide–alkyne cycloaddition (CuAAC) and amine–isothiocyanate coupling were implemented for "click" multiconjugation, both ligation chemistries warranting full homogeneity. Interestingly, in both types of macrocycles incorporation of linear six-carbon chains

![Fig. 1](image1.png)  
**Fig. 1** Schematic representation of the amphiphilic polycationic \(\beta\)-cyclodextrin (\(\beta\)CD) and calix[4]arene (CA\(_4\)) gene vector prototypes in the optimal skirt-type and upper-rim protonable cone arrangements, respectively.

![Fig. 2](image2.png)  
**Fig. 2** Schematic representation of the lead \(\beta\)CD and CA\(_4\) vectors 1a and 2d.
into the hydrophobic domain provided the best results. The
tetradecacationic \( \beta \text{CD} \) derivative 1a, displaying a dendritic
presentation of primary amino groups and fourteen hexanoyl
chains at the secondary hydroxyls, and the tetraarginine-CA4
conjugate 2d, bearing four hexyl ether substituents, were
identified as lead compounds within each category (Fig. 2).

In our ongoing efforts to develop CD and CA-based artificial
viruses for drug and gene delivery,\(^{16}\) evaluating the properties
of structurally related series of CD and CA vectors in the same
cell systems was highly sought. By combining our expertise on
the chemistry and supramolecular properties of both archetypes we are in the position to underpin whether or not the

--

**Results and discussion**

**Synthesis**

The known polycationic amphiphilic \( \beta \text{CD} \) derivatives 1a–c,
bearing aminothiourea head groups, have been previously
shown to exhibit promising transfection capabilities both
in vitro\(^{\text{9b}}\) and, in the case of 1a, also in vivo.\(^{\text{14d}}\) For
this reason, they were selected as the \( \beta \text{CD} \) representatives in sub-
library I for the purpose of this study. The synthesis of the new
analogues 2a–c (Scheme 1), incorporating the same cationic
heads in the CA4 series, started from the known 5,11,17,23-
tetraamino-25,26,27,28-tetrakis(\( \alpha \)-hexylidyloxy)calix[4]arene 3\(^{106}\)
which was transformed into the pivotal tetraisothiocyanate 4
using an excess of the isothiocyanation reagent carbon di-
sulfide/bis-(\( \text{tert} \)-butyl) carbonate.\(^{18}\) Reaction of 4 with bis(\( \text{2-
}\text{tert})\)-butyloxycarbonylaminooethyl) amine (\( \rightarrow 5 \)), bis(\( \text{2-
} \text{tert}-\text{butyloxy})\)carbamoylaminooethyl) amine (\( \rightarrow 6 \)) and 2-
\( \text{tert}-\text{butyloxycarbonylaminooethylamine} \) (\( \rightarrow 7 \)), in the presence of
triethylamine, and the removal of the carbamate protecting
group in the thiourea adducts by trifluoroacetic acid (TFA)-pro-
moted hydrolysis in the presence of triethylsilane (TES)
afforded the target CA4 facial amphiphiles 2a–c in high yield.
The final compounds were isolated as the corresponding octa-
(2a and 2b) or tetra-hydrochloride salts (2c) after repeated dis-
solution/evaporation cycles from methanolic HCl and final lyo-
philisation (Scheme 1).

The lead calixarene derivative 2d was the reference com-
 pound that inspired sub-library II. The homologous-\( \beta \text{CD} \) represen-
tative 1d was obtained by hepta-amidation of the per-(\( \text{C-6})\)\,-cysteaminyl-per-(\( \text{O-2,O-3})\)-hexanoyl \( \beta \text{CD} \) precursor 8, accessible
in only three steps from \( \beta \text{CD},^{\text{9b,19}} \) with the commercial pro-
tected arginine derivative 9 (\( \rightarrow 10 \)) and final deprotection
(Scheme 2).

The presence of the cysteaminyl connector releases the
steric constrain at the primary \( \beta \text{CD} \) rim and warrants homo-
genous multiconjugation even for hyperbranched architec-
2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulfonyl. HBTU: DIPEA: Diisopropyl ethyl amine. TIS: triisopropylsilane.

Reagents and conditions: (a) HBTU, DIPEA, DCM, rt, 12 h, 68%; (b) (i) CS₂, Et₃N, EtOH, rt, 2 h, 88%; (ii) Boc₂O, DMAP, EtOH, 0 °C → rt, 2 h, 88%; (iii) NH(CH₂CH₂NHBoc)₂, Et₃N, DCM, rt, 12 h, quantitative; (c) H₂NCH₂CH₂N(CH₂CH₂NHBOc)₂, Et₃N, DCM, rt, 12 h, 99%; (d) NH₂CH₂CH₂NHBOc, Et₃N, DCM, rt, 1.2 h, 99%; (e) (i) TFA–TES–DCM, 5 min, rt; (ii) HCl, 99%.

Scheme 1 Synthesis of polyaminothioureido CA₄ derivatives 2a–c.

Reagents and conditions: (a) (i) CS₂, Et₃N, EtOH, rt, 2 h; (ii) Boc₂O, DMAP, EtOH, 0 °C → rt, 2 h, 88%; (b) NH(CH₂CH₂NHBOc)₂, Et₃N, DCM, rt, 12 h, quantitative; (c) H₂NCH₂CH₂N(CH₂CH₂NHBOc)₂, Et₃N, DCM, rt, 12 h, 99%; (d) NH₂CH₂CH₂NHBOc, Et₃N, DCM, rt, 1.2 h, 99%; (e) (i) TFA–TES–DCM, 5 min, rt; (ii) HCl, 99%.

Scheme 2 Synthesis of amide-linked polyarginine βCD derivative 1d.

Reagents and conditions: (a) HBTU, DIPEA, DCM, rt, 12 h, 68%; (b) (i) 95 : 2.5 : 2.5 TFA–TIS–DCM, rt, 1 h; (ii) 0.1 M HCl, quantitative. Pbf: 2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulfonyl. HBTU: o-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate. DIPEA: Diisopropyl ethyl amine. TIS: triisopropyldisilane.

βCD- and CA₄-based polycationic amphiphiles 1a–f and 2a–f to complex and protect DNA was first examined by electrophoresis mobility shift assays (EMSA) and by determining their capability to prevent intercalation of GelRed™ (Biotium) used to stain the DNA filaments. The luciferase-encoding plasmid DNA (pDNA) pTG11236 (pCMV-SV40-luciferase-SV40pA, 5739 base pairs) was employed in this experimental setting at protonable nitrogen/phosphorous (N/P) ratios 1, 2, 5, 10 and 20. The data (Fig. 4) evidenced that all the tested derivatives were able to fully complex and protect pDNA at N/P > 2 as indicated by the absence of free mobile plasmid in the corresponding lanes. As a general trend, sub-library I compounds 1a,b or 2a,b, displaying a dendritic presentation of primary amino groups, were more efficient at condensing pDNA than the linear aminothioureido derivatives 1c or 2c. In sub-library II, amide connecters 1d or 2d) performed better than the triazol linkers (1e or 2e). Overall, βCD-
scaffolded polycations achieved full neutralization of pDNA and fully blocked GelRed™ intercalation at lower N/P ratios as compared with the respective CA4 counterparts.

Nanocondensates formulated with 1a–f or 2a–f and the pTG11236 plasmid at N/P 5 and 10, for which EMSA indicated full pDNA complexation and protection, were characterized by dynamic light scattering (DLS) to determine the average hydrodynamic size and by mixed-mode measurement-phase analysis light scattering (M3-PALS) to measure the ζ-potential (Fig. 5). Apart from the two guanidino macrocycles 1f and 2f at N/P = 5 that formed aggregates of 160 and 175 nm, respectively, all the other compounds gave rise to supramolecular species of similar size in the range of 80–120 nm hydrodynamic diameter with a rather low polydispersity. The observed size decrease on going from N/P = 5 to N/P = 10 for most of the nanoparticles, in spite of the equivalent results obtained in EMSA, is indicative of different compaction states. Accordingly, the ζ-potential, which is positive for both N/P values, was higher at N/P = 10 (Fig. 5 and Tables S1 and S2 in the ESI†). No significant changes in size or ζ-potential were observed at higher N/P ratios (data not shown).

Transmission electron microscopy (TEM) of the nanocomplexes formulated at N/P 10 confirmed their relatively small size and low polydispersity (Fig. 6). As previously observed for amphiphilic βCD aminothiourea polycations, a snake-like ultra-thin structure revealing an alternating arrangement of high (dark) and low (light) electron density regions was apparent, independently of the sub-library or the macrocyclic scaffold. The dark regions account for the DNA chain, whereas the lighter regions probably correspond to bilayers of the facial amphiphile. This scenario strongly suggests a compaction mechanism involving the polynucleotide chain acting as a template for the alignment of the cationic clusters, a process driven initially by electrostatic interactions. Zipping of the bilayers with simultaneous expulsion of hydration water must then take place through hydrophobic contacts implying the hydrophobic domains, leading to the final nanocondensates (Fig. 6).
Atomic force microscopy (AFM) further confirmed the size, spherical shape and monomolecular DNA character of the nanocomplexes formulated with $1a$–$f$ or $2a$–$f$, irrespective of the nature of the protonable groups or the scaffold. Most interestingly, this technique allowed the monitoring of DNA compaction by increasing concentrations of the vector. The green fluorescence protein (GFP)-encoding plasmid pEGFP-C1 (4731 bps) was used for this purpose. As an example, Fig. 7 shows the images obtained for sub-library III polyguanidine derivatives $1f$ and $2f$. At N/P 0.5 complexation is incomplete and free pDNA filaments of about 0.5 μm in length can be observed together with partially shrunk plasmids. At N/P 5 all DNA molecules appear as individual nanocondensates.

In vitro transfection of COS-7 cells

The βCD and CA₄-pDNA nanocomplexes (CDplexes and calixplexes) obtained by formulation of $1a$–$f$ or $2a$–$f$ and the luciferase-encoding plasmid pEGFP-C1 (4731 bps) was used for this purpose. As an example, Fig. 7 shows the images obtained for sub-library III polyguanidine derivatives $1f$ and $2f$. At N/P 0.5 complexation is incomplete and free pDNA filaments of about 0.5 μm in length can be observed together with partially shrunk plasmids. At N/P 5 all DNA molecules appear as individual nanocondensates.
Barring the guanidine CA₄ cluster 2f, all the βCD:pDNA and CA₄-pDNA formulations showed transfection efficiencies that compare favourably with the results obtained for bPEI polyplexes and all, without exception, exhibited more favorable cell viabilities (Fig. 9). Within sub-library I and III derivatives, βCD-scaffolded vectors 1a–c and 1f proved superior to the homologous CA₄ partners 2a–c and 2f, but excepting for the latter pair, differences remained within one order of magnitude. In the group of vectors displaying arginine groups (sub-library II) the influence of the scaffold is less evident. On the other hand, in the CA₄ series the presence of amide connectors (compound 2d) was somehow more favourable as compared to triazol linkers (compound 2e). Indeed, compounds 1d, 1e and 2d were as efficient as the lead aminothiourea representative 1a and similarly preserved the transfection capabilities in serum-containing medium. The most striking observation is the dramatic drop in transfection efficiency on comparing sub-libraries II and III. The compounds bearing the simple guanidinium units showed by far the lowest transfection efficacy among all the synthesized compounds. This result suggests that the presence in the vectors of nitrogen atoms with the ability to reversibly shift from protonated to neutral state in a physiological pH window is advantageous, probably by imparting buffering capabilities to the corresponding nanoparticles, thereby facilitating endosome escape through the so-called proton sponge mechanism.²⁴

Transfection efficiency towards COS-7 cells was also determined using the GFP-encoding plasmid pEGFP-C1 and directly monitoring by fluorescence microscopy the expression of the GFP protein into the cells as a consequence of successful transfection. Rather than the amount of protein produced, this experiment aims at evaluating the proportion of cells that is effectively transfected by each polycationic cluster:pDNA formulation. Transfection efficiency is then reported as percentage of transfected cells (Fig. 11). Given that cytotoxicity has a strong impact in this assay, for each vector the concentration producing the best compromise between cell viability and transfection efficiency in the range of 1.25–10 μM, was used. At concentrations lower than those selected the cell viability was comparable or higher but the percentage of transfected cells was lower while at higher concentrations cytotoxicity was too high. Cell viabilities, determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method (see the ESIF for Experimental details) at the concentrations studied in this experimental setting, are collected in Fig. 10. In addition to PEI-formulated polyplexes, lipoplexes formulated with commercial Lipofectamine® (LTX) were included as positive controls. Parallel experiments were also conducted in the presence of dioleoylphosphatidylethanolamine (DOPE), a commonly used transfection adjuvant²³ that has been previously found to improve the transfection efficiency of CA₄-scaffolded polycationic clusters in some cases.¹⁰a–c,¹⁶ Cells treated only with DOPE were then used as negative controls.
Overall, the results obtained using this evaluation protocol (Fig. 11) qualitatively paralleled those previously obtained with the luciferase-encoding plasmid. Thus, the two guanidinocarboxylate derivatives 1f and 2f included in sub-library III exhibited the poorer transfection abilities among all vectors assayed, with a percentage of transfected cells close to zero. In the polyaminothiourea series (sub-library I) βCD-scaffolded derivatives 1a–e proved superior to the corresponding CA4 analogues 2a–c bearing identical cationic heads, whereas in sub-library II amide-linked derivatives 1d and 2d provided higher transfection efficiencies as compared with triazol-linked analogues 1e and 2e. In any case, only the nanocomplexes formulated with the two lead compounds in sublibraries I and II, namely, the dendritic βCD aminothiourea 1a and the amide-linked CA4 tetraarginine derivative 2d, rivalled lipoplexes formulated with LTX. Co-formulation with DOPE was detrimental in most cases with the notable exceptions of the calixplexes obtained from compounds 2b and 2e, for which a quite significant enhancement in the percentage of transfected COS-7 cells was observed.

**Fig. 10** Cell viability of COS-7 cells (MTT determination) in the presence of nanocomplexes formulated with the pEGFP-C1 and βCD or CA4 polycations 1a–f or 2a–f at their optimal concentration (μM) with and without DOPE (1:2 vector–DOPE molar ratio). Data for lipoplexes formulated with Lipofectamine® (LTX), and polyplexes formulated with polyethyleneimine (PEI) are also shown. C.T.A.: commercial transfection agent.

**Fig. 11** *In vitro* transfection efficiency in COS-7 cells in the presence of nanocomplexes formulated with the pEGFP-C1 and βCD or CA4 polycations 1a–f or 2a–f at their optimal concentration (μM) with and without DOPE (1:2 vector–DOPE molar ratio). Data for lipoplexes formulated with Lipofectamine® (LTX), and polyplexes formulated with polyethyleneimine (PEI) are also shown. C.T.A.: commercial transfection agent.

**Fig. 12** Cell viability of RD-4 cells (MTT determination) in the presence of nanocomplexes formulated with the pEGFP-C1 and βCD or CA4 polycations 1a–f or 2a–f at their optimal concentration (μM) with and without DOPE (1:2 vector–DOPE molar ratio). Data for lipoplexes formulated with Lipofectamine® (LTX), and polyplexes formulated with polyethyleneimine (PEI) are also shown. C.T.A.: commercial transfection agent.

**Fig. 13** *In vitro* transfection efficiency in RD-4 cells in the presence of nanocomplexes formulated with the pEGFP-C1 and βCD or CA4 polycations 1a–f or 2a–f at their optimal concentration (μM) with and without DOPE (1:2 vector–DOPE molar ratio). Data for lipoplexes formulated with Lipofectamine® (LTX), and polyplexes formulated with polyethyleneimine (PEI) are also shown. C.T.A.: commercial transfection agent.

**In vitro transfection of the human rhabdomyosarcoma RD-4 cell line**

Human rhabdomyosarcoma RD-4 cells are a kind of cancer cells of connective tissues. The difficulties of the treatment and the impossibility, in many cases, of removing the tumor make this cell line of high medical relevance for gene therapy. Moreover, it is a cell line which is particularly very difficult to transfect. The protocol based on the use of the pEGFP-C1 and fluorescence microscopy monitoring of the percentage of cells expressing GFP after treatment with the nanocomplexes formulated with the optimal concentration of each molecular vector, eventually co-formulated with DOPE, was applied. This choice is consistent with previous studies on the ability of calixplexes to mediate transfection in this particular cell line. The corresponding cell viability and transfection data are collected in Fig. 12 and 13, respectively. Formulations prepared with LTX and PEI were used as positive controls whereas parallel experiments with DOPE alone were conducted as a negative control.

Most of the nanocomplexes formulated with the βCD or CA4 polycationic amphiphiles 1a–f or 2a–f led to GFP expression in the RD-4 cell line, but only the lead compound...
in each series, namely the dendritic aminothiourea \( \beta CD \) derivative \( 1a \) and the arginine \( CA_4 \) derivative \( 2d \), performed better than the references LTX and PEI. Both \( 1a \) and \( 2d \) showed their best efficiency when formulated without the adjuvant (Fig. 14). Actually, as already observed in COS-7 cells, the incorporation of DOPE was generally detrimental for the activity of the tested ligands. The data confirms the high transfection efficiency of the argininocalixarene \( 2d \) in RD-4 cells. While in the experiments with COS-7 cells differences in transfection efficiencies between vectors in the tested library remained modest, in the case of RD-4 cells the transfection efficiency of the argininocalixarene \( 2d \) stands out of the rest, with an exceptional 75% of cells successfully transfected. The dendritic aminothiourea \( \beta CD \) derivative \( 1a \), which was the best performing system in the COS-7 cell line, achieved 50% of RD-4 cells transfected, meaning that the optimal vector depends on the target cell. In any case, with few exceptions, such as the significant transfection level observed for the tetraguanidine \( CA_4 \) derivative \( 2f \) in this assay, the data within a series follow the same trends already observed in COS-7 cells, but differences are quantitatively more pronounced. Thus, the proportion of transfected cells drops from 50% or 25% to almost zero on going from the dendritic tetracationic derivatives \( 1a \) or octacationic \( 2a \) to the linear heptacationic \( 1c \) or tetracationic \( 2e \) analogues. A high cationic density thus seems to be critical for the successful transfection of RD-4 cells.

When comparing homologous \( \beta CD \) and \( CA_4 \) derivatives in each sub-library, barring the \( 1a/2a \) pair the calixarene derivatives were generally superior to the cyclodextrins vectors, which is the opposite situation to that encountered in COS-7 cells. It has been previously advanced that \( \beta CD \) facial amphiphiles can interact with cholesterol in the cell membrane through inclusion complex formation and that this interaction facilitates caveolin-mediated endocytosis (CME) of the corresponding CDplexes. Indeed, CME has been shown to be by far the most productive internalization route for CDplexes. Since caveolin is down-regulated in rhabdomyosarcoma, it can be expected that the efficiency of \( \beta CD \)-based vector will be decreased in RD-4 as compared with COS-7 cells. It is interesting to speculate that calixplexes can enter the cell through alternative caveolin-independent routes that remain productive regarding transfection, which may be at the origin of the outstanding result obtained with compound \( 2d \). Exploring this hypothesis is currently underway in our laboratories.

Conclusions

In summary, we have demonstrated that the approach based in the installation of counter-directional multi-head/multi-tail cationizable/O-hexanoyl or O-hexyl domains onto a \( \beta \)-cyclodextrin or a calix[4]arene platform provides facial amphiphiles with gene delivery capability. Total control of the homogeneity at the molecular level is warranted in homologous series of compounds, allowing reliable structure–activity relationship studies. The components of the three sub-libraries considered in this study, namely compounds featuring aminothiourea, arginine and guanidine clusters were all able to condense pDNA into self-assembled nanocomplexes through a process that involves electrostatic vector–DNA interactions and hydrophobic vector–vector interactions, resulting in a well-ordered arrangement of alternated DNA chains and vector bilayers. As a general trend, increasing the density of protonable groups had a beneficial impact in transfection capabilities provided that amino groups, with buffering capabilities, were present in the structure. The effect of the macrocyclic core on this was more evident when comparing different cell lines. In epithelial COS-7 cells from apes, \( \beta CD \) formulated CDplexes exhibited a higher transfection efficiency than the homologous \( CA_4 \)-formulated calixplexes, while the reverse situation was encountered in human RD-4 cells. This switch can be tentatively ascribed to the operation of different cell uptake mechanisms that affect in a dissimilar manner the fate of CDplexes and calixplexes. In any case, this work provides clues for the rational design of new molecular gene delivery systems and validates the strategy based on systematic structural modifications in CD and CA-based facial amphiphiles and structure–activity relationship studies for the identification of optimal candidates for gene therapy applications.

Experimental

General methods

Bis(2-tert-butyloxycarbonylaminoethyl) amine and bis(2-tert-butyloxycarbonylaminoethyl) 2-aminoethyl amine were obtained according to literature procedures. Optical rotations were measured at \( 20 \pm 2 \) °C in 1 dm tubes on a Jasco P-2000 polarimeter. \( ^1 \)H and \( ^{13} \)C NMR spectra were recorded at 500 (125.7) MHz with a Bruker 500 DRX magnet. 1D TOCSY, 2D COSY, HMQC and HSQC experiments were used to assist on NMR assignments. Thin-layer chromatography (TLC) was carried out on aluminum sheets coated with silica gel 60 F254 Merck with visualization by UV light and by charring with ethanolic 10% \( \text{H}_2\text{SO}_4 \) or 0.1% ninhydrin. Column chromatography was carried out on Silica Gel 60. ESI mass spectra were recorded on a Bruker Daltonics Esquire6000TM ion-trap mass...
spectrometer; in some cases, C11 was added as the catingion agent. MALDI-TOF mass spectra were registered in a Bruker Daltonics AutoFlex instrument in the linear positive mode with pulse ion extraction; 2,5-dihydroxybenzoic acid (DHB) was used as a desorption matrix. Elemental analyses were carried out at the Instituto de Investigaciones Químicas (Sevilla, Spain).

5,11,17,23-Tetraolthioxyacetan-25,26,27,28-tetrakis-(n-hexyloxy)-calix[4]arene (4). To a solution of 5,11,17,23-tetraaminoo-25,26,27,28-tetrakis-(n-hexyloxy)calix[4]arene (3, 150 mg, 0.183 mmol) in absolute EtOH (4 mL) under reduced pressure and the residue was purified by column chromatography (1:3 DCM-cyclohexane). Yield: 181 mg (88%); Rf = 0.67 (1:3 DCM-cyclohexane); 1H NMR (400 MHz, CDCl3); δ 6.56 (s, 8 H, Ar), 3.45 (d, J = 10.2 Hz, 4 H, ArCH2Ar), 3.83 (t, J = 5.7 Hz, 8 H, CH2-1-tet), 3.09 (d, J = 10.2 Hz, 4 H, ArCH2Ar), 1.89–1.77 (m, 8 H, CH2-2-hex), 1.41–1.28 (m, 24 H, CH2-3-hex, CH2-4-hex, CH2-5-hex), 0.97–0.94 (m, 12 H, CH3-6-hex); 13C NMR (100.6 MHz, CDCl3); δ 155.7, 135.9, 134.3 (NCS), 125.7, 125.6 (Ar), 75.9 (C1-3-tet), 32.1 (C1-3-tet), 30.9 (ArCH2Ar), 30.2 (C2-hex), 25.9 (C4-hex), 22.9 (C5-hex), 14.2 (C6-hex); ESI-MS: m/z: 1011.1 [M + Na]+; Anal. calcd for C56H68N4O4S4: C 67.98, H 7.62, N 11.79, S 5.40. Found: C 60.52, H 8.58, N 11.62, S 5.24.

5,11,17,23-Tetra-[(N,N'-bis-(2-tert-butoxycarbonylamino)ethyl)thio]ureido]-25,26,27,28-tetrakis-(n-hexyloxy)-calix[4]arene (6). A solution of 4 (40 mg, 0.040 mmol) in dry DCM (3 mL) was added dropwise to a solution of bis-(2-tert-butoxycarbonylamino)ethanol (67.4 mg, 0.19 mmol) and Et3N (40 μL, 0.28 mmol) in dry DCM (3 mL). The mixture was stirred overnight at rt. The solvent was removed under vacuum and the residue was purified by column chromatography (19:1 DCM-MeOH). Yield: 95 mg (99%); Rf = 0.56 (9:1 DCM-MeOH); 1H NMR (300 MHz, CD3OD); δ 6.721 (bs, 8 H, Ar), 4.47 (d, J = 12.9 Hz, 4 H, ArCH2Ar), 3.93 (m, 8 H, CH2-1-hex), 3.69–3.53 (m, 8 H, CH2-1-hex), 3.20 (d, J = 13.3 Hz, 4 H, ArCH2Ar), 3.07 (t, J = 6.4 Hz, 16 H, CH2-1-chBNBOc), 2.77–2.65 (m, 8 H, CH2-1-chBNBOc), 2.64–2.53 (m, 16 H, CH2-1-chBNBOc), 2.06–1.89 (m, 8 H, CH2-1-hex), 1.62–1.25 (m, 96 H, CMe3, CH2-2-hex, CH2-3-hex, CH2-4-hex), 1.02–0.87 (m, 12 H, CH3-6-hex); 13C NMR (75 MHz, CD3OD, 313 K); δ 181.7 (CS), 158.4 (CO), 155.9–126.1 (Ar), 80.3 (CMe3), 76.6 (C1-hex), 55.3 (CH2BNBOc), 54.4 (CH2CH2BNBOc), 43.8 (CH3CH2BNBOc), 40.1 (CH2CH2CH2BNBOc), 33.3 (C3-hex), 32.0 (ArCH2Ar), 31.5 (C2-hex), 29.0 (CMe3), 27.3 (C3-hex), 23.9 (C5-hex), 14.4 (C6-hex); ESI-MS: m/z: 2397.3 [M + Na]+, 1290.6 [M + 2Na]+; Anal. calcd for C210H163N16O32S16: C 60.68, H 8.66, N 11.79, S 5.40. Found: C 60.52, H 8.58, N 11.62, S 5.24.
curred for C_{60}H_{135}Cl_{12}N_{20}O_{8}S_{4}: C 47.76, H 7.62, N 13.92, S 6.38. Found: C 47.67, H 7.72, N 13.90, S 6.29.

5.11,17,23-Tetraaminothioureido)-25,26,27,28-tetrakis-(n-hexyloxy)calix[4]arene (7). A solution of 8 (484 mg, 0.85 mmol) in dry DCM (3 mL) was added dropwise to a solution of 2-tetraaminothioureido-benzamidoxylamine (276 mg, 0.62 mmol) in dry DCM (3 mL). The mixture was stirred overnight at rt, the solvent was removed under vacuum and the residue was purified by column chromatography (95:5 → 9:1 DCM-MeOH). Yield: 138 mg (99%); R_t = 0.61 (9:1 DCM-MeOH); 1H NMR (400 MHz, CD3OD): δ 6.68 (bs, 8 H, Ar), 4.46 (d, J = 12.7 Hz, 4 H, ArCH2Ar), 3.93 (t, J = 7.9 Hz, 8 H, CH2-1Hex), 3.65 (t, J = 6.0 Hz, 8 H, CH2NHCS), 3.34–3.16 (m, 12 H, ArCH2Ar, CH2-NHBOC), 2.06–1.91 (m, 8 H, CH2-2Hex), 1.55–1.32 (m, 60 H, CH2-3Hex, CH2-4Hex, CH2-5Hex, CMe3), 1.01–0.92 (m, 12 H, CH2-6Hex); 13C NMR (100.6 MHz, CD3OD): δ 181.6 (CIS), 158.8 (CO), 155.8–125.9 (Ar), 80.2 (CMe), 76.7 (C-1Hex), 45.9 (CH2NHCS), 40.8 (CH2-NHBOC), 33.4 (C-3Hex), 31.9 (ArCH2Ar), 31.6 (C-2Hex), 28.9 (CMe), 27.3 (C-4Hex), 24.1 (C-5Hex), 14.5 (C-6Hex); ESI-MS: m/z 1651.8 [M + Na]+, 1667.8 [M + K]+; Anal. calc. for C_{64}H_{42}N_{32}O_{12}S; C 61.88, H 8.16, N 10.31, S 7.87. Found: C 61.85, H 8.29, N 10.24, S 7.79.

5.11,17,23-Tetraaminothioureido)-25,26,27,28-tetrakis-(n-hexyloxy)-calix[4]arene (2c). A solution of 7 (40 mg, 25 μmol) in DCM-TFA-TES (87.5:10:2.5, 0.5 mL) was stirred at 0 °C for 2 h. The solvent was removed and the residue was precipitated and washed with Et2O. Then the solid was dissolved in an aqueous 0.1 M HCl solution and concentrated to yield the product as hydrochloride. Yield: 33.8 mg (99%); 1H NMR (500 MHz, CD3OD): δ 6.72 (bs, 8 H, Ar), 4.47 (d, J = 13.2 Hz, 4 H, ArCH2Ar), 3.98–3.85 (m, 16 H, CH2-1Hex, CH2-NHCS), 3.26–3.13 (m, 12 H, ArCH2Ar, CH2NH), 2.02–1.88 (m, 8 H, CH2-2Hex), 1.56–1.35 (m, 24 H, CH2-3Hex, CH2-4Hex, CH2-5Hex, CH2-6Hex), 0.99–0.91 (m, 12 H, CH2-6Hex); 13C NMR (75 MHz, CD3OD): δ 182.8 (CS), 156.0–125.7 (Ar), 76.7 (C-1Hex), 42.8 (CH2-NHCS), 40.8 (CH2NH), 33.4 (C-3Hex), 31.9 (ArCH2Ar), 31.5 (C-2Hex), 27.3 (C-4Hex), 24.0 (C-5Hex), 14.5 (C-6Hex); ESI-MS: m/z 1291.4 [M + Cu]+; Anal. calc. for C_{64}H_{42}N_{32}O_{12}S_{4}HCl: C 55.88, H 7.62, N 12.22, S 9.32. Found: C 55.59, H 7.56, N 11.92, S 9.03.

Heptakis[6-(2-argamido-3-aminoethyl)aminocyclohexanol-2,2,4,6,7-pentamethyldienobenzofuran-5-sulfonyl]-arginine-N-4-(boc)-heptahydrochloride (1d). A solution of 10 (375 mg, 6 μmol) in TFA-TIS-H2O (95:2.5:4, 4 mL) was stirred at rt for 1 h. The solvent was removed under reduced pressure and coevaporated several times with H2O. The residue was dissolved in an aqueous 0.1 M HCl solution and freeze-dried to obtain the product as hydrochloride. Yield: 41 mg (99%); [α]_D = +97 (c 1.0 in DMSO); 1H NMR (500 MHz, DMSO-d6, 323 K): δ 8.96 (bs, 7 H, NHCO), 8.51–8.29 (m, 14 H, NH2Arg), 7.93–7.77 (bs, 7 H, NH guanidine), 7.44–7.09 (m, 21 H, NH, NH guanidine), 5.25 (t, J = 9.0 Hz, 7 H, H-3), 5.09 (bs, 7 H, H-1), 4.69 (bd, 7 H, H-2), 4.17–4.07 (m, 21 H, 7 H, H-5), 3.99–3.83 (m, 14 H, CH2-5Arg-1H), 3.43–3.32 (bs, 14 H, CH2N2), 3.29–3.19 (bs, 7 H, CH2-Arg), 3.15–2.99 (m, 14 H, 6-Ha, 6-Hb), 2.87–2.66 (m, 14 H, CH2S), 2.44–2.29 (m, 7 H, CH2-2Hex), 2.26–2.11 (m, 7 H, CH2-4Hex), 1.92–1.80 (m, 14 H, CH2-Arg), 1.70–1.58 (m, 14 H, CH2-3Arg), 1.58–1.45 (m, 28 H, CH2-5Hex), 1.35–1.19 (bs, 56 H, CH2-4Hex, CH2-5Hex), 0.93–0.78 (m, 42 H, CH2-6Hex); 13C NMR (125.7 MHz, DMSO-d6, 323 K): δ 175.7, 174.5 (CO ester), 177.8 (CO amide), 161.2 (CN), 99.4 (C-1), 81.3 (C-4), 74.3 (C-5), 73.1 (C-2), 72.9 (C-3), 55.1 (CH2-2Arg), 43.7 (CH2-Arg), 42.4 (CH2-NHCO), 36.5, 36.3 (C-2Hex C-6), 35.3 (CHS), 33.9, 33.8 (C-4Hex), 31.4 (CH2-2Arg), 27.2 (CH2-4Arg), 26.9, 26.8 (C-3Hex), 24.9, 24.8 (C-5Hex), 16.65, 16.63 (C-6Hex); MALDI-MS: m/z 4017.86 [M + H]+; Anal. calc. for C_{182}H_{168}N_{50}O_{87}S_{25}Os: C 49.68, H 7.73, N 10.54, S 4.82. Found: C 47.01, H 7.50, N 10.48, S 4.75.

Heptakis[6-(2-argamido-3-aminoethyl)aminocyclohexanol-2,2,4,6,7-pentamethyldienobenzofuran-5-sulfonyl]-arginine-N-propargylamide (11). A mixture of 10-N,N,N-Propargylamide (1.9 mmol), DIPEA (0.78 mL, 4.5 mmol) and HBTU (865 mg, 2.28 mmol) were dissolved in dry DMF (15 mL), under an Ar atmosphere. After stirring for 30 min at rt, propargylamine (0.146 mL, 2.28 mmol) was added and the mixture was stirred for 15 h.
The solvent was removed under reduced pressure and the residue was dissolved in EtOAc (15 mL), the organic layer was washed with aqueous saturated NaHCO₃ (15 mL), H₂O (15 mL), dried (MgSO₄), filtered and concentrated. The residue was purified by column chromatography (1:2 → 3:1 EtOAc–cyclohexane). Yield: 935 mg (87%); R₉ = 0.41 (19:1 DCM–MeOH); [α]₂⁰ = +0.9 (c 1.0 in MeOH). ¹H NMR (500 MHz, CDCl₃): δ 7.34 (1s, 3 H, NHCO₂), 6.27 (m, 3 H, NH), 5.59 (bs, 1 H, N2/Boc), 4.20 (bs, 1 H, CH₂-Arg), 3.99 (m, 2 H, CH₂-alkyne), 3.27 (bs, 2 H, CH₂-5Arg), 2.96 (s, 2 H, CH₂-Arg), 2.51 (s, 3 H, Me₂Pbf), 2.50 (s, 3 H, Me₂Pbf), 2.18 (t, J = 2.5 Hz, 1 H, CH-alkyne), 2.09 (s, 3 H, Me₂Pbf), 1.81 (m, 2 H, CH₂-3Arg), 1.60 (m, 2 H, CH₂-3Arg), 1.46 (s, 6 H, CMe₂Pbf), 1.41 (s, 9 H, CMe₃); ¹³C NMR (100.6 MHz, CDCl₃): δ 165.9 (CO amide), 159.0 (Car), 156.8 (CN), 156.1 (CO carbamate), 138.3–117.6 (Car), 86.4 (CMe₂), 80.2 (CMe), 79.6 (Cq allkine), 71.4 (CH alkyne), 60.4 (CH₂NHBoc), 43.2 (CH₂Pbf, CH₂-5Arg), 29.9 (CH₂-4Arg), 29.1 (CH₂-6Arg), 28.6 (CMe₂), 28.3 (CMe), 19.3, 17.9, 12.5 (Me₂Pbf); ESI-MS: m/z 1306.3 [M + Na]²⁺; Anal. calcd for C₁₈₅H₂₅₀Cl₁₄N₅₄O₄₉: C 48.57, H 7.25, Cl 10.62, N 19.75; found: C 48.30, H 7.25, Cl 10.90.

Heptakis[6-deoxy-2,3-di-O-hexanoyl-6-(4-[N₉-tetrtbutylocarbonyln-N₉-tetrtbutylocarbonyl-N₉-tetrtbutylocarbonyl-N₉-tetrtbutylocarbonyl]-1H-1,2,3-triazol-1-yl)cyclomaltoheptaose (13). To a solution of heptakis[6-azido-6-deoxy-2,3-di-O-hexanoyl]cyclomaltoheptaose (12, 88 mg, 33 μmol) in acetone (5 mL), N₉-tetrt-butyl,hex-2,4,6,7-pentamethylenehydroborenafuran-5-sulfonyl]-L-arginine-N-aminomethyl]-1H,1,2,3-triazol-1-yl)cyclomaltoheptaose (13). Yield: 35.7 mg (quantitative); [α]₂⁰ = +46.5 (c 1.0 in DMF); ¹H NMR (500 MHz, DMSO-d₆) δ 8.99 (bs, 7 H, NH₃), 7.99 (m, 21 H, CH₃triazole, NH₂ arginine), 7.18 (bs, 21 H, NH₂ guanidine, NH guanidine), 5.41–5.37 (m, 14 H, H-3, H-1), 4.68–4.63 (m, 21 H, H-2, CH₂NHCO amide), 4.51 (m, 7 H, H-5), 4.36–4.34 (m, 7 H, H-6a), 4.23–4.21 (m, 7 H, H-6b), 3.92 (m, 7 H, CH₂), 3.72 (bt, 7 H, H-4), 3.19 (m, 14 H, CH₂-5Arg), 2.37–1.93 (m, 28 H, CH₂-4Hex, CH₂-3Hex, CH₂-5Hex), 1.86–1.79 (m, 14 H, CH₂-4Arg, CH₂-5Arg, CH₃triazole, 1.37–1.20 (m, 56 H, CH₂-4Hex, CH₂-5Hex, 0.94–0.80 (bs, 21 H, CH₂-6Hex); ¹³C NMR (125.7 MHz, DMSO-d₆); δ 172.8, 171.8 (CO ester), 169.1 (CO amide), 157.7 (CN guanidine), 144.2 (C-4triazole), 125.7 (C-5triazole), 102.5 (C-1), 77.3 (C-4), 70.3 (C-3), 70.1 (C-5), 69.7 (C-2), 52.5 (CH₂-2Arg), 49.9 (CH₂NHCO), 40.7 (CH-5-Arg), 34.9 (C-6), 33.8, 33.7 (C-4Hex), 31.2, 31.1 (C-4-Hex), 28.5 (CH₂-3Arg), 24.3, 24.2 (C-5Hex, CH₂-4Arg), 22.2, 22.1 (C-5Hex), 13.9 (C-6Hex); MALDI-MS: m/z 4163.60 [M + H]; Anal. calcd for C₁₇₈H₂₃₀Cl₁₄N₄₂O₄₉: C 48.57, H 7.25, Cl 10.62, N 19.75; found: C 48.33, H 6.82, N 16.49.

5,11,17,23-Tetraformyl-25,26,27,28-tetrakis(n-hexyl-oxycalix[4]arene (15). A solution of hexamethyletriamine (16.57 g, 118.3 mmol) in TFA (150 mL) was stirred at 100 °C for 10 min. Then, 25/26,27,28-tetras(n-hexyl-oxycalix[4]arene (14, 2.5 g, 3.29 mmol) was added and the mixture was stirred at reflux for 2 h. The reaction was quenched by the addition of HCI M (400 mL) and stirred for 3 h. The aqueous layer was extracted twice with DCM (250 mL); the combined organic phases were washed with a saturated aqueous solution of NaHCO₃ (200 mL) and brine (200 mL), dried (Na₂SO₄) and filtered. The solvent was removed under reduced pressure. The product was purified by crystallization from hexane (50 mL). Yield: 2.75 g (96%); R₉ = 0.20 (2:3 EtOAc–cyclohexane); ¹H NMR (300 MHz, CDCl₃) δ 9.58 (s, 4 H, CHO), 7.15 (s, 8 H, Ar), 4.49 (d, J = 13.8 Hz, 4 H, ArCHCO₂Ar), 3.96 (t, J = 7.5 Hz, 8 H, CH₂-1Hex), 3.34 (d, J = 13.8 Hz, 4 H, ArCH₂CO₂Ar), 2.00–1.80 (m, 8 H, CH₂-2Hex), 1.50–1.20 (m, 24 H, CH₂-3Hex, CH₂-4Hex, CH₂-5Hex, 1.00–0.80 (m, 12 H, CH₂-6Hex); ¹³C NMR (100.6 MHz, CDCl₃) δ 191.3 (CHO), 162.0–130.2 (Ar), 75.8 (C-1Hex), 31.9 (C-3Hex), 30.9 (ArCH₂), 30.3 (C-2Hex), 25.8 (C-4Hex), 22.8 (C-5Hex), 14.0 (C-6Hex); ESI-MS: m/z 895.9 [M + Na]; Anal. calcd for C₁₆₈H₂₅₁O₄₉: C 77.03, H 8.31. Found: C 77.68, H 8.04.

5,11,17,23-Tetrahydroxymethyl-25,26,27,28-tetras(n-hexyl-oxycalix[4]arene (16). To a suspension of 15 (910 g, 1.04 mmol) in absolute EtOH (50 mL) at 0 °C, NaBH₄ (0.24 g, 6.25 mmol) was added. The mixture was stirred at rt for 18 h. Then, 1 M HCl (20 mL) was added and the solvents were evaporated under reduced pressure. EtOAc (50 mL) was added to this and the organic layer was washed with a saturated aqueous solution of NaHCO₃ (50 mL) and H₂O (50 mL), dried over Na₂SO₄, and...
5.11,17,23-Tetramethylcalix[4]arene (17). To a solution of 16 (600 mg, 0.68 mmol) in dry DCM (10 mL), SOCl2 (0.99 mL, 13.60 mmol) was added. The reaction mixture was refluxed for 1 h. Then, the solvent was evaporated and the crude was dissolved in EtOAc (15 mL). The organic layer was washed with H2O (15 mL), dried over MgSO4, filtered and concentrated. The residue was purified by column chromatography (cyclohexane→1:1 cyclohexane–EtOAc). Yield: 186 mg (95%); Rf = 0.29 (19:1 cyclohexane–EtOAc).

1H NMR (300 MHz, CDCl3) δ 6.61 (bs, 8 H, Ar), 4.45 (d, J = 13.2 Hz, 4 H, Ar-CH2Ar), 3.95 (s, 8 H, CH2N3), 3.89 (t, J = 7.5 Hz, 8 H, CH2CH2), 1.36 (d, J = 13.2 Hz, 4 H, Ar-CH2CH2Ar), 1.98–1.85 (m, 8 H, CH2CH2), 1.48–1.30 (m, 24 H, CH2-3Hex, CH2-4Hex, CH2-5Hex, CH2-6Hex), 0.93 (t, J = 6.9 Hz, 12 H, CH3-6Hex); 13C NMR (75 MHz, CDCl3) δ 162.1–128.2 (Ar), 75.0 (C-1Hex), 53.8 (CH2N3), 31.7 (C-3Hex), 30.4 (Ar-CH2Ar), 29.9 (C-2Hex), 25.5 (C-4Hex), 22.4 (C-5Hex), 13.7 (C-6Hex); ESI-MS: m/z 1002.9 [M + Na]+; Anal. calc’d for C56H76Cl4O14: C 60.87, H 7.48, N 13.85, S 3.96. Found: C 60.80, H 7.43, N 13.89, S 3.82.

5.11,17,23-Tetra-(1H,1,2,3-triazol-1-yl)-calix[4]arene octahydrochloride (2e). A solution of 14 (20 mg, 6.18 μmol) in TFA–TIS–H2O (95:2.5:2.5, 2 mL) was stirred at rt for 1 h. The solvent was removed under reduced pressure and the residue was washed with EtOAc (15 mL). Then the solid was dissolved in 0.1 M HCl solution followed by evaporation under reduced pressure to obtain the product as hydrochloride. Yield: 13 mg (99%). [α]D = +21.4 (c 1.0 in MeOH); 1H NMR (300 MHz, CDCl3) δ 8.21 (bs, 4 H, CH-1triazole), 6.71 (bs, 8 H, Ar), 5.39 (bs, 8 H, CH2NHCO amide), 4.75–4.50 (m, 8 H, Ar-CH2), 3.85 (t, J = 7.39 Hz, 4 H, CH2-2Arg), 3.92 (t, J = 7.4 Hz, 8 H, CH2CH2), 3.27–3.08 (m, 12 H, CH2-3Arg, ArCH2Ar), 2.08–1.82 (m, 16 H, CH2-3Arg, CH2-4Arg), 1.78–1.61 (m, 8 H, CH2-2triazole), 1.53–1.33 (m, 24 H, CH2-3triazole, CH2-4triazole, CH2-5triazole), 1.00–0.90 (m, 12 H, CH3-6hex), 13C NMR (75 MHz, CDCl3) δ 170.2 (CO amide), 158.6 (CN guanidine), 158.2, 137.0 (Ar), 136.8 (C-4triazole), 130.0, 129.8 (Ar), 129.7 (C-5triazole), 126.6 (C-1triazole), 156.6 (C-2triazole), 134.0 (C-3triazole), 122.6 (C-5triazole), 116.6 (Ar), 86.2 (CMe2Ph), 79.1 (CMe6), 75.1 (C-1triazole), 54.2 (CH-2Arg), 53.3 (CH3NHCO), 42.4 (CMe2Ph), 39.8 (CH2-3Arg), 34.3 (CH2Ar), 31.8 (C-3Hex), 30.1 (ArCH2Ar), 29.0 (CH2-3Arg), 27.2 (CMep2Ph, CMe8), 25.8 (C-4triazole), 25.4 (CH-4Arg), 22.5 (C-5triazole), 18.2, 17.0 (MePbf), 13.0 (C-6triazole), 11.1 (MePbf); ESI-MS: m/z 1640.4 [M + 2Na]+; Anal. calc’d for C156H144N32O8S8Cl8: C 67.02, H 5.77, N 20.09. Found: C 65.23, H 8.05, N 19.82.

5.11,17,23-Tetra-4-(1-arginine-N-amidinomethyl)-1H,1,2,3-triazol-1-yl-calix[4]arene tetrahydrochloride (20). A solution of 18 (300 mg, 0.306 mmol) in EtOAc–EtOH (1:1, 50 mL), a catalytic amount of Pd/C (30 mg) and 1 M HCl (4 mL) were added. Hydrogenation was carried out at 2 atm for 48 h. Then, the catalyst was filtered and the solvent was removed under reduced pressure. Yield: 313 mg (99%); 1H NMR (300 MHz, CDCl3) δ 6.60 (bs, 4 H, CH2NHCO amide), 5.40–4.36 (m, 12 H, CH2Ar, ArCH2Ar), 4.02 (bs, 4 H, CH2-2Arg), 3.86 (t, J = 7.4 Hz, 8 H, CH2-1triazole), 3.19–3.02 (m, 12 H, ArCH2Ar, CH2-5Arg), 2.96 (s, 8 H, CH2Pbf), 2.55 (s, 12 H, MePbf), 2.50 (s, 12 H, MePbf), 2.05 (s, 12 H, MePbf), 1.94–1.85 (m, 8 H, CH2-2Hex), 1.79–1.29 (m, 100 H, CH2Hex, CH2-4Hex, CH2-5Hex, CMe8, CMe2Pbf, CH2-3Arg, CH2-4Arg), 0.98–0.88 (m, 12 H, CH2-6Hex); 13C NMR (100.6 MHz, CD3OD) δ 175.0–126.7 (Ar), 162.1, 157.1, 156.6 (C=O amide), 158.4 (CN guanidine), 156.4 (Ar), 156.2 (CO carbamate), 145.0 (C-4triazole), 138.0–128.8 (CMePbf, Ar), 127.9, 124.5 (Ar), 122.6 (C-5triazole), 116.9 (Ar), 86.2 (CMe2Ph), 79.1 (CMe6), 75.1 (C-1triazole), 54.2 (CH-2Arg), 53.3 (CH3NHCO), 42.4 (CMe2Ph), 39.8 (CH2-3Arg), 34.3 (CH2Ar), 31.8 (C-3Hex), 30.1 (ArCH2Ar), 29.0 (CH2-3Arg), 27.2 (CMep2Ph, CMe8), 25.8 (C-4triazole), 25.4 (CH-4Arg), 22.5 (C-5triazole), 18.2, 17.0 (MePbf), 13.0 (C-6triazole), 11.1 (MePbf); ESI-MS: m/z 1640.4 [M + 2Na]+; Anal. calc’d for C156H144N32O8S8Cl8: C 67.02, H 5.77, N 20.09. Found: C 65.23, H 8.05, N 19.82.
75.2 (C-1Hex), 42.6 (CH₂NH₂), 31.9 (C-3Hex), 30.3 (ArCH₂Ar), 30.1 (C-2Hex), 25.8 (C-4Hex), 22.5 (C-5Hex), 13.1 (C-6Hex); ESI-MS: m/z 877.6 [M + H]⁺, 899.8 [M + Na]⁺; Anal. calcd for C₃₈H₅₁N₂₁O₇₀S₇: C 56.43, H 8.10, N 6.37, S 4.86. Found: C 56.26, H 8.00, N 6.12, S 4.51.

**Heptakis[6-(2-di-tert-butoxycarbonylguanidino)ethylthio]-2,3-di-O-hexanoyl]cyclomaltoheptaose (21).** To a solution of heptakis[2,3-di-O-hexanoyl-6-(2-aminoethylthio)]cyclomaltoheptaose heptahydrochloride (8, 50 mg, 15 μmol) in dry DCM (5 mL), under an Ar atmosphere, Et₂N (61 μL, 440 μmol) and N-N’-di-tert-butoxycarbonyl-N’’-triflylguanidine (86 mg, 220 μmol) were added. The reaction mixture was stirred overnight. The reaction mixture was washed with an aqueous solution of 2 M KHSO₄. The organic layer was washed with a saturated aqueous solution of NaHCO₃, dried (MgSO₄), filtered and concentrated. The residue was purified by column chromatography (2:1 DCM–cyclohexane – EtOAc–cyclohexane). Yield: 67 mg (99%); Rₖ = 0.75 (1:3 EtOAc–cyclohexane); [α]D = +30.7 (c 1.0 in MeOH); ¹H NMR (300 MHz, CDCl₃, 313 K): δ 5.33 (t, J = 7.1 Hz, J₂=1.4 = 8.6 Hz, H₃), 5.14 (d, J₁=1.2 = 3.7 Hz, 7 H, H-1), 4.88 (dd, 7 H, H-2), 4.26–4.15 (m, 7 H, H-5), 3.93 (t, J = 7.2 Hz, H-4), 3.78–3.53 (m, 14 H, H-6a, H-6b), 3.16 (bs, 14 H, CH₂S), 2.58–2.85 (m, 14 H, CH₂S), 2.51–2.14 (m, 28 H, CH₂-2Hex), 1.74–1.56 (m, 28 H, CH₂-3Hex), 1.57–1.43 (bs, 126 H, CH₃), 1.45–1.24 (m, 56 H, CH₂-4Hex, CH₂-5Hex), 1.02–0.85 (m, 42 H, CH₂-6Hex); ¹³C NMR (75 MHz, CDCl₃, 313 K): δ 174.5, 173.4 (CO ester), 164.6 (CN), 157.3, 154.2 (CO carbamate), 98.6 (C-1), 84.5 (C-4), 80.4 (CMe₃), 73.0 (C-5), 71.9 (C-3), 71.5 (C-2), 41.4 (C-6), 35.2, 35.0 (C-2Hex), 34.1 (CH₂S), 32.6, 32.5 (C-4Hex), 28.9, 28.6 (CMe₃), 25.6 (C-3Hex), 23.6, 23.5 (C-5Hex), 14.5 (C-6Hex); ESI-MS: m/z 2332.2 [M + 2Na]⁺, 1562.7 [M + 3Na]⁺; Anal. calcd for C₃₁₀H₄₁₁N₂₁O₂₀S: C 56.43, H 8.10, N 6.37, S 4.86. Found: C 56.26, H 8.00, N 6.12, S 4.51.

**Heptakis[6-(guanidinothio)-2,3-di-O-hexanoyl]cyclomaltoheptaose hydrochloride (1f).** A solution of 16 (60 mg, 13 μmol) in DCM–TFA (1:1, 2 mL) was stirred at rt for 3 h. The solvent was eliminated under reduced pressure and coevaporated several times with water. The residue was dissolved in a 0.1 M HCl solution and freeze-dried to yield the product as hydrochloride. Yield: 45 mg (99%); [α]D = +68.3 (c 1.0 in DMF); ¹H NMR (300 MHz, CDCl₃): δ 5.39 (t, J = 7.1 Hz, J₂=1.4 = 9.4 Hz, H-3), 5.18 (d, J₁=1.2 = 3.5 Hz, 7 H, H-1), 4.86 (m, 7 H, H-2), 4.16–4.07 (m, 7 H, H-5), 3.96 (t, J = 7.4 Hz, H-4), 3.48 (t, 14 H, CH₂NH₂), 3.20–3.11 (m, 14 H, H-6a, H-6b), 2.97–2.85 (m, 14 H, CH₂S), 2.55–2.21 (m, 28 H, CH₂-2Hex), 1.72–1.55 (m, 28 H, CH₂-3Hex), 1.41–1.26 (m, 56 H, CH₂-4Hex, CH₂-5Hex), 0.99–0.87 (m, 42 H, CH₂-6Hex); ¹³C NMR (125.7 MHz, DMSO-d₆, 323 K): δ 172.2, 171.2 (CO), 156.8 (CN), 96.1 (C-1), 78.0 (C-4), 71.2 (C-5), 69.7 (C-3), 69.8 (C-2), 45.5 (C-6), 40.6 (CH₂NH₂), 33.1, 32.9 (C-2Hex), 32.1 (CH₂S), 30.6, 30.4 (C-4Hex), 23.6, 23.5 (C-3Hex), 21.5 (C-5Hex), 13.3, 13.2 (C-6Hex); ESI-MS: m/z 1609.6 [M + 2H]⁺, 1073.0 [M + 3H]⁺, 805.1 [M + 4H]⁺; Anal. calcd for C₁₄₇H₁₇₂Cl₄N₂₁O₂₄S₇·7H₂O: C 49.06, H 7.84, N 8.17, S 6.24. Found: C 49.81, H 7.78, N 8.03, S 6.15.

5,11,17,23-Tetraguanidinomethyl-25,26,27,28-tetrasik(3-hexyloxy)calix[4]arene tetrahydrochloride (2f). To a solution of 17 (69 mg, 0.037 mmol) in dry dioxane (7 mL), TES (59 μL, 0.37 mmol) and 37% HCl (500 μL) were added. The mixture was stirred for 24 h at rt. Then, the solvents were evaporated under reduced pressure. The product was precipitated with Et₂O (6 mL) and dried under reduced pressure. Yield: 44 mg (99%); ¹H NMR (300 MHz, CDCl₃): δ 6.75 (s, 8 H, Ar), 4.49 (d, J = 13.2 Hz, 4 H, ArCH₂Ar), 4.15 (s, 8 H, CH₂NH₂), 3.93 (d, J = 7.2 Hz, 8 H, CH₂-1Hex), 3.23 (d, J = 13.2 Hz, 4 H, ArCH₂Ar), 2.05–1.95 (m, 8 H, CH₂-2Hex), 1.55–1.31 (m, 24 H, CH₂-3Hex, CH₂-4Hex, CH₂-5Hex), 1.01–0.93 (m, 12 H, CH₂-6Hex); ¹³C NMR (100.6 MHz, CDCl₃): δ 158.3 (CN), 157.6–129.0 (Ar), 76.5 (C-1Hex), 45.9 (CH₂NH₂), 33.6 (C-3Hex), 31.9 (ArCH₂Ar), 31.5 (C-2Hex), 27.3 (C-4Hex), 24.0 (C-5Hex), 14.5 (C-6Hex); ESI-MS: m/z 1045.89 [M + H]⁺; Anal. calcd for C₁₀₀H₁₅₆N₁₂O₂₀: C 70.95, H 8.12, N 14.11. Found: C 65.03, H 8.32, N 9.10.

**Acknowledgements**

L.G.-Y. is an FPU fellow. This study was financially supported by the Spanish Ministerio de Economía y Competitividad (contract numbers SAF2013-44021-R and CTQ2010-15848), the Junta de Andalucía (contract number FQM2012-1467), the Italian Ministry of Instruction, University and Research (MIUR, PRIN2010[MAZML MultiNanolta), the COST actions MultiGlycoNano (CM1102) and Supramolecular Chemistry in Water (CM1005), and the European Regional Development Funds (FEDER and FSE). Technical assistance from the research support services of the University of Seville (CITIUS) and Centro Interdipartimentale di Misure (CIM) of Parma University is also acknowledged.
Notes and references

1 (a) A. Aiuti, F. Cattaneo, S. Galimberti, U. Benninghoff, B. Cassani, L. Callegaro, S. Scaramazza, G. Andolfi, M. Mirolo, I. Brigida, A. Tabucchi, F. Carlucci, M. Eibl, M. Aker, S. Slavin, H. Al-Mousa, A. Al Ghanaium, A. Ferster, A. Duppenthaler, L. Notarangelo, U. Wintergerst, R. H. Buckley, M. Bregn, S. Marktel, M. G. Valsecchi, P. Rossi, F. Ciceri, R. Miniero, C. Bordignon and M. G. N. Roncarolo, *Engl. J. Med.*, 2009, 360, 447; (b) F. Mavilio, P. Pellegrini, S. Ferrari, F. Di Nunzio, E. Di Iorio, A. Recchia, G. Maruggi, G. Ferrari, E. Provasi, C. Bonini, S. Capurro, A. Conti, C. Magnoni, A. Giannetti and M. De Luca, *Nat. Med.*, 2006, 12, 1397; (c) S. L. Murphy and K. A. High, *Br. J. Hematol.*, 2008, 140, 479; (d) P. Arumugam and P. Malik, *Hematol. Am. Soc. Hematol. Educ. Program*, 2010, 445; (e) M. De Luca, G. Pellegrini and F. Mavilio, *Br. J. Dermatol.*, 2009, 161, 19; (f) A. Biffi, E. Montini, L. Liorio, M. Cesani, F. Fumagalli, T. Plati, C. Baldoli, S. Martino, A. Calabria, S. Canale, F. Benedicenti, G. Vallanti, L.Biasco, S. Leo, N. Kabbara, G. Zanetti, W. Rizzo, N. A. Mehta, M. Cicalese, M. Casiraghi, J. Boelens, U. Del Carro, D. Dow, M. Schmidt, A. Assanelli, V. Neduva, C. Di Serio, E. Stupka, J. Gardner, C. von Kalle, C. Bordignon, F. Ciceri, A. Rolvelli, M. Roncarolo, A. Aiuti, M. Sessa and L. Naldini, *Science*, 2013, 341, 1233158; (g) A. Aiuti, L. Biasco, S. Scaramuzzoa, F. Ferrua, M. Cicalese, C. Baricordi, F. Dionisio, A. Calabria, S. Giannelli, M. Castiello, M. Bosticardo, C. Evangelio, A. Assanelli, M. Casiraghi, S. Di Nunzio, L. Callegaro, C. Benati, P. Rizzardi, D. Pellin, C. Di Serio, M. Schmidt, C. Von Kalle, J. Gardner, N. Mehta, V. Neduva, D. Dow, A. Galy, R. Miniero, A. Finocchi, A. Metin, P. Banerjee, J. Orange, S. Galimberti, M. Valsecchi, A. Biffi, E. Montini, A. Villa, F. Ciceri, M. Roncarolo and L. Naldini, *Science*, 2013, 341, 853; (h) M. Morille, C. Passirani, A. Vonarbourg, A. Clavreul and J. P. Benoit, *Biomaterials*, 2008, 29, 3477.

2 Gene Therapy Clinical Trials Worldwide provided by the J. Gene Med. ( http://www.wiley.com/legacy/wileychi/genmed/clinical/).

3 R. Srinivas, S. Samanta and A. Chaudhuri, *Chem. Soc. Rev.*, 2009, 38, 3326–3338.

4 (a) S. D. Li and L. Huang, *J. Controlled Release*, 2007, 123, 181; (b) M. A. Mintzer and E. E. Simanek, *Chem. Rev.*, 2009, 109, 259.

5 (a) A. Rajala, Y. Wang, Y. Zhu, M. Ranjo-Bishop, J.-X. Ma, C. Mao and R. V. S. Rajala, *Nano Lett.*, 2014, 9, 5257; (b) M. E. Davis, *Mol. Pharmaceutics*, 2009, 6, 659.

6 (a) C. Ortiz Mellet, J. M. García Fernández and J. M. Benito, *Chem. Soc. Rev.*, 2011, 40, 1586; (b) J. M. García Fernández, J. M. Benito and C. Ortiz Mellet, *Pure Appl. Chem.*, 2013, 85, 1825; (c) L. Wang, L. Li, Y. Fan and H. Wang, *Adv. Mater.*, 2013, 25, 3888.

7 (a) S. Srinivasachari, K. M. Fichter and T. M. Reineke, *J. Am. Chem. Soc.*, 2008, 130, 4618; (b) N. Mortzis, M. Paravatou, I. M. Mavridis, M. L. Roberts and K. Yannakopoulou, *Chem. – Eur. J.*, 2008, 14, 4188; (c) S. Menuel, S. Fontanay, I. Clarot, R. E. Duval, L. Diez and A. Marsura, *Bioconjugate Chem.*, 2008, 19, 2357–2362; (d) R. Lalor, J. L. DiCesso, A. Mueller and S. E. Matthews, *Chem. Commun.*, 2007, 4907; (e) V. Bennevault-Celton, A. Urbach, O. Martin, C. Pichon, P. Guégan and P. Midoux, *Bioconjugate Chem.*, 2011, 22, 2404.

8 For a review, see: (a) C. Ortiz Mellet, J. M. Benito and J. M. García Fernández, *Chem. – Eur. J.*, 2010, 16, 6728. For additional recent examples of polycationic facial amphiphiles based on macrocyclic scaffolds, see: (b) Y. Yao, M. Xue, J. Chen, M. Zhang and F. Huang, *J. Am. Chem. Soc.*, 2012, 134, 15712; (c) Y. Yao, M. Xue, Z. Zhang, M. Zhang, Y. Wang and F. Huang, *Chem. Sci.*, 2013, 4, 3667.

9 (a) A. Diaz-Moscoso, P. Balbuena, M. Gómez-García, C. Ortiz Mellet, J. M. Benito, L. Le Gourrièrec, C. Di Giorgio, P. Vierling, A. Mazzaglia, N. Micalli, J. Defaye and J. M. García Fernández, *Chem. Commun.*, 2008, 2001; (b) A. Diaz-Moscoso, L. Le Gourrièrec, M. Gómez-García, J. M. Benito, P. Balbuena, F. Ortega-Caballero, N. Guillouteau, C. Di Giorgio, P. Vierling, J. Defaye, C. Ortiz Mellet and J. M. García Fernández, *Chem. – Eur. J.*, 2009, 15, 12871; (c) A. Méndez-Ardoy, M. Gómez-García, C. Ortiz Mellet, N. Sevillano, M. D. Girón, R. Salto, F. Santoyo-González and J. M. García Fernández, *Org. Biomol. Chem.*, 2009, 7, 2681; (d) A. Martínez, C. Bienvenu, J. L. Jiménez Blanco, P. Vierling, C. Ortiz Mellet, J. M. García Fernández and C. Di Giorgio, *J. Org. Chem.*, 2013, 78, 8143.

10 (a) M. Dudić, A. Colombo, F. Sansone, A. Casnati, G. Donofrio and R. Ungaro, *Tetrahedron*, 2004, 60, 11613; (b) F. Sansone, M. Dudić, G. Donofrio, C. Rivetti, L. Baldini, A. Casnati, S. Cellai and R. Ungaro, *J. Am. Chem. Soc.*, 2006, 128, 14528; (c) V. Bagnacani, F. Sansone, G. Donofrio, L. Baldini, A. Casnati and R. Ungaro, *Org. Lett.*, 2008, 10, 3953; (d) V. Bagnacani, V. F. L. Fantuzzi, F. Sansone, G. Donofrio, A. Casnati and R. Ungaro, *Bioconjugate Chem.*, 2012, 23, 993.

11 (a) A. M. O’Mahony, B. M. D. C. Godinho, J. Ogier, M. Devocelle, R. Darcy, J. F. Cryan and C. M. O’Driscoll, *ACS Chem. Neurosci.*, 2012, 3, 744; (b) V. Villari, A. Mazzaglia, R. Darcy, C. M. O’Driscoll and N. Micalli, *Biromacromolecules*, 2013, 14, 811; (c) A. M. O’Mahony, S. Desgranges, J. Ogier, A. Quinlan, M. Devocelle, R. Darcy, J. F. Cryan and C. M. O’Driscoll, *Pharm. Res.*, 2013, 30, 1086; (d) J. McCarthy, M. J. O’Neill, L. Bourre, D. Walsh, A. Quinlan, G. Hurley, J. Ogier, F. Shanahan, S. Melgar, R. Darcy and C. M. O’Driscoll, *J. Controlled Release*, 2013, 168, 28; (e) B. M. D. C. Godinho, D. J. McCarthy, C. Torres-Fuentes, C. J. Beltrán, J. McCarthy, A. Quinlan, R. Ogier, R. Darcy, C. M. O’Driscoll and J. F. Cryan, *Biomaterials*, 2014, 489.

12 R. V. Rodik, A. S. Klymchenko, N. Jain, S. I. Miroshnichenko, L. Richert, V. I. Kalchenko and Y. Mély, *Chem. – Eur. J.*, 2011, 17, 5526.
13 C. Bienvenu, A. Martínez, J. L. Jiménez Blanco, C. Di Giorgio, P. Vierling, C. Ortiz Mellet, J. Defaye and J. M. García Fernández, *Org. Biomol. Chem.*, 2012, **10**, 5570.

14 (a) A. Díaz-Moscoso, D. Vercauteren, J. Rejman, J. M. Benito, C. Ortiz Mellet, S. C. De Smedt and J. M. García Fernández, *J. Controlled Release*, 2010, **143**, 318; (b) A. Díaz-Moscoso, N. Guilloteau, C. Bienvenu, A. Méndez-Ardoy, J. L. Blanco, J. M. Benito, L. Le Gourriérec, C. Di Giorgio, P. Vierling, J. Defaye, C. Ortiz Mellet and J. M. García Fernández, *Biomaterials*, 2011, **32**, 7263; (c) A. Méndez-Ardoy, N. Guilloteau, C. Di Giorgio, P. Vierling, F. Santoyo-González, C. Ortiz Mellet and J. M. García Fernández, *J. Org. Chem.*, 2011, **76**, 5882; (d) A. Méndez-Ardoy, K. Uribiola, C. Aranda, C. Ortiz-Mellet, J. M. García-Fernández and C. Tros de Ilarduya, *Nat. Nanotechnol.*, 2012, **7**, 1849.

15 F. Ortega-Caballero, C. Ortiz Mellet, L. Le Gourriérec, N. Guilloteau, C. Di Giorgio, P. Vierling, J. Defaye and J. M. García Fernández, *Organ Lett.*, 2008, **10**, 5143.

16 V. Bagnacani, V. Franceschi, M. Bassi, M. Lomazzi, G. Donofrio, F. Sansone, A. Casnati and R. Ungaro, *Nat. Commun.*, 2013, **4**, 1721.

17 (a) L. Gallego-Yerga, M. Lomazzi, F. Sansone, C. Ortiz Mellet, A. Casnati and J. M. García Fernández, *Chem. Commun.*, 2014, **50**, 7440; (b) L. Gallego-Yerga, M. J. González-Alvárez, N. Mayordomo, F. Santoyo-González, J. M. Benito, C. Ortiz Mellet, F. Mendicuti and J. M. García Fernández, *Chem. – Eur. J.*, 2014, **20**, 6622.

18 H. Munch, J. S. Hansen, M. Pittelkow, J. Christensen and U. Boas, *Tetrahedron Lett.*, 2008, **49**, 3117.

19 M. Gómez-García, J. M. Benito, D. Rodríguez-Lucena, J.-X. Yu, K. Chmurski, C. Ortiz Mellet, R. Gutiérrez-Gallego, A. Maestre, J. Defaye and J. M. García Fernández, *J. Am. Chem. Soc.*, 2005, **127**, 7970.

20 (a) E. M. Aguilar Moncayo, N. Guilloteau, C. Bienvenu, J. L. Jiménez Blanco, C. Di Giorgio, P. Vierling, J. M. Benito, C. Ortiz Mellet and J. M. García Fernández, *New J. Chem.*, 2014, **38**, 5215; (b) M. Gómez-García, J. M. Benito, A. P. Butera, C. Ortiz Mellet, J. M. García Fernández and J. L. Jiménez Blanco, *J. Org. Chem.*, 2012, **77**, 1273; (c) M. Gómez-García, J. M. Benito, R. Gutiérrez-Gallego, A. Maestre, C. Ortiz Mellet, J. M. García Fernández and J. L. Jiménez Blanco, *Org. Biomol. Chem.*, 2010, **8**, 1849.

21 (a) S. Srinivasachari, Y. Liu, G. Zhang, L. Prevette and T. M. Reineke, *J. Am. Chem. Soc.*, 2006, **128**, 8176; (b) P. Midoux, C. Pichon, J. J. Yaouane and P. A. Jaffres, *Br. J. Pharmacol.*, 2009, **157**, 166.

22 (a) M. Meldal and C. W. Tornoe, *Chem. Rev.*, 2008, **108**, 2952; (b) P. Cintas, A. Barge, S. Tagliapietra, L. Boffa and G. Cravotto, *Nat. Protoc.*, 2010, **5**, 607; (c) C. W. Tornoe, C. Christensen and M. Meldal, *J. Org. Chem.*, 2002, **67**, 3057; (d) V. V. Rostovtsev, L. G. Green, V. V. Fokin and K. B. Sharpless, *Angew. Chem., Int. Ed.*, 2002, **41**, 2596.

23 H. Ihm and K. Paek, *Bull. Korean Chem. Soc.*, 1995, **16**, 71.

24 (a) M.-H. Louis, S. Dutoyt, Y. Denoux, P. Erbacher, E. Deslandes, J.-P. Behr, P. Gauduchon and L. Poulain, *Cancer Gene Ther.*, 2006, **13**, 367; (b) O. Boussif, F. Lezoualch, M. A. Zanta, M. D. Mergny, D. Scherman, B. Demeneix and J.-P. Behr, *Proc. Natl. Acad. Sci. U. S. A.*, 1995, **92**, 7297.

25 (a) L. Wasungu and D. Hoekstra, *J. Controlled Release*, 2006, **116**, 255; (b) H. Farhood, N. Serbina and L. Huang, *Biochim. Biophys. Acta*, 1995, **1235**, 289.

26 S. Rossi, P. L. Poliani, C. Missale, E. Monti and A. Fanzani, *J. Cell. Mol. Med.*, 2011, **15**, 2553.